Company Overview
| Stock Name | 方達控股公司 |
|---|---|
| Stock Code | 01521 |
| Company Full Name | 方達控股公司 |
| Industry | 醫療保健 |
| Principal Activities | 公司主要向制藥及農藥公司提供實驗室及相關服務以及生物等效性研究。 |
| Listing Date | 2019-05-30 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 香港銅鑼灣希慎道33號利園一期19樓1920室 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.frontagelab.com |
| Share Registrar | |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 3.20 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 41.5% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 642,444,800 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 3.35 |
|---|---|
| First Day Open | HK$ 3.68 |
| First Day Change | 4.69% |
| First Day Volume | 280684000.0 |
| First Day Turnover | 1007630000.0 |
Use of Proceeds
| Use of Proceeds | 1、預計于上市后12至18個月內將所分配金額約272百萬港元（或所得款項凈額的約20%）用于以下預期開支： （1）約81百萬港元的款項將用于改善、升級及擴大我們位于美國的現有設施； （2）約46百萬港元的款項將用于我們計劃于中國上海張江高科技園租賃的總建筑面積約為40,000至50,000平方呎的新設施的翻新； （3）約39百萬港元的款項將用于改善本集團于美國及中國運營的系統、流程及應用程式； （4）約106百萬港元的款項將用于為我們的設施購買新設備及技術，以及于美國及中國聘請更多科學家； 2、約545百萬港元的款項（或所得款項凈額的約40%）于上市后12至18個月內將用于有機地擴大及拓寬我們的能力及服務范圍； 3、約408百萬港元的款項（或所得款項凈額的約30%）將用于通過潛在收購； 4、約136百萬港元的款項（或所得款項凈額的約10%）將用作為營運資金及一般企業用途，包括（尤其是）改善我們業務的常規制度、經營及流程。 |
|---|
Underwriting Syndicate
Joint Sponsors (2)
Merrill Lynch (Asia Pacific) Limited CE AAC198
高盛（亚洲）有限责任公司 CE ACC536
Overall Coordinators (4)
Merrill Lynch (Asia Pacific) Limited CE AAC198
高盛（亚洲）有限责任公司 CE ACC536
中信里昂证券有限公司 CE AAB893
海通国际证券有限公司 CE AAF806
Joint Bookrunners (4)
Merrill Lynch (Asia Pacific) Limited CE AAC198
高盛（亚洲）有限责任公司 CE ACC536
中信里昂证券有限公司 CE AAB893
海通国际证券有限公司 CE AAF806
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Hillhouse Funds | 392,422,400 HKD | — | 24.40% | — | 6 months | 2019-11-30 |
| 2 | Worldwide Healthcare Trust PLC | 117,721,600 HKD | — | 7.30% | — | 6 months | 2019-11-30 |
| 3 | 景林资产管理有限公司 | 156,966,400 HKD | — | 9.80% | — | 6 months | 2019-11-30 |
Directors & Management
| Chairman | 李松 |
|---|---|
| Company Secretary | 張盈倫 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 杭州泰格醫藥科技股份有限公司(51.22%);李松(8.19%) |
|---|
